H. Lundbeck A/S (Lundbeck) today announced the acceptance of its new drug application (NDA) for Vyepti® (eptinezumab) by the Ministry of Health, Labor and Welfare (MHLW) in Japan.

Inconsistent wording, inaccessible files and outdated references don’t just annoy regulators — they confuse customers and train LLMs on the wrong story.

As-A-Service Market by Service Type (Ride Hailing, Car Sharing, Micro Mobility, and Other), Business Model ...